+375 (212) 36-47-77
EN RU

VALGANTSIKLOVIR-RN

VALGANTSIKLOVIR-RN
Composition per tablet:
active substance: valganciclovir - 450 mg (as valganciclovir hydrochloride - 496.3 mg);
excipients: microcrystalline cellulose, crospovidone, povidone K30, magnesium stearate; shell (polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc).
Indications for use:
Valganciclovir-Rn is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).
Valganciclovir-Rn is indicated for the prevention of CMV infection in CMV-negative adults and children (aged 0 to 18 years) who underwent transplantation of solid organs from CMV-positive donors. Back to list
Rubikon 2020
Site development: One Click